Title
Physical activity as a strategy for maintaining tobacco abstinence: a randomized trial.

Permalink
https://escholarship.org/uc/item/99b9r4n4

Journal
Preventive medicine, 47(2)

ISSN
1096-0260

Authors
Prochaska, Judith J
Hall, Sharon M
Humfleet, Gary
et al.

Publication Date
2008-08-01

Peer reviewed
Physical activity as a strategy for maintaining tobacco abstinence: A randomized trial

Judith J. Prochaska *, Sharon M. Hall, Gary Humfleet, Ricardo F. Muñoz, Victor Reus, Julie Gorecki, Dixie Hu

University of California, San Francisco, Department of Psychiatry, USA

Abstract

Objectives. For smoking cessation, physical activity (PA) may help manage withdrawal symptoms, mood, stress, and weight; yet studies of PA as an aid for smoking cessation have been mixed. This study examined: (1) the impact of an extended relapse prevention program on increasing moderate to vigorous PA (MVPA) in adults enrolled in a tobacco cessation treatment trial; (2) whether changes in MVPA were associated with sustained abstinence from smoking; and (3) mechanisms by which MVPA may support sustained abstinence from smoking.

Methods. In a randomized controlled trial conducted from 2003–2006 in San Francisco, California, 407 adult smokers received a 12 week group-based smoking cessation treatment with bupropion and nicotine patch with the quit date set at week 3. At week 12, participants were randomized to no further treatment or to 40 weeks of bupropion or placebo with or without an 11-session relapse prevention intervention of which 2 sessions (held at weeks 16 and 20) focused on PA. Participants receiving the PA intervention (n=163) received a pedometer, counseling to increase steps 10% biweekly towards a 10,000 steps/day goal, and personalized reports graphing progress with individualized goals. The International Physical Activity Questionnaire assessed weekly minutes of MVPA at baseline and weeks 12 and 24. Sustained abstinence from tobacco at week 24 was validated with expired carbon monoxide.

Results. In a repeated mixed model analysis, intervention participants significantly increased their MVPA relative to control participants, F(1,475)=3.95, p=0.047. Pedometer step counts also increased significantly, t(23)=2.36, p=0.027, though only 15% of intervention participants provided 6 weeks of pedometer monitoring. Controlling for treatment condition, increased MVPA predicted sustained smoking abstinence at week 24, odds ratio=1.84 (95% CI: 1.07, 3.05). Among participants with sustained abstinence, increased MVPA was associated with increased vigor (r=0.23, p=0.025) and decreased perceived difficulty with staying smoke-free (r=−0.21, p=0.038).

Conclusion. PA promotion as an adjunct to tobacco treatment increases MVPA levels; changes in MVPA predict sustained abstinence, perhaps by improving mood and self-efficacy.

© 2008 Elsevier Inc. All rights reserved.

Introduction

Tobacco use is the leading preventable cause of death in the United States (CDC, 2005). Only 3% to 5% of smokers who try to quit unaided achieve prolonged abstinence at 6 to 12 months (Hughes et al., 2004). Even with evidence-based smoking cessation treatments, relapse is common (Piasecki, 2006), often in response to mood changes (Shiffman and Waters, 2004), withdrawal symptoms (Piasecki et al., 2000), weight gain (Borrelli et al., 2001), and cravings (Killen and Fortmann, 1997).

Physical activity (PA) may be useful in addressing the physiological and psychological causes of relapse to smoking (Rook et al., 1999; Ussher et al., 2001). A systematic review of 12 studies comparing a bout of exercise with a passive condition reported a positive effect for reducing cigarette cravings, negative affect, withdrawal symptoms, and smoking behavior (Taylor et al., 2007). Two additional studies concluded the effect of PA was irrespective of the intensity level (moderate vs. vigorous). Further, the mechanism by which PA reduces desire to smoke and nicotine withdrawal symptoms is distinct from simple cognitive distraction (Daniel et al., 2006).

Though most people who quit smoking will gain less than 10 lb (Williamson et al., 1991), weight gain concerns are predictive of smoking initiation, reluctance to quit smoking, and smoking relapse (Gritz and Crane, 1991; Klesges et al., 1989; Perkins et al., 1995). For managing weight gain associated with quitting smoking, clinical practice guidelines recommend PA, rather than dieting (Fiore et al., 2000). In general practice, PA is an effective strategy for weight gain prevention (USDHHS, 1996).

Adults who smoke tend to be less physically active than nonsmokers (Kaczynski et al., 2008). Unger (1996) observed that adults preparing to quit smoking exercised more than smokers in the earlier stages of change. Further, a significant positive association has
been found between one’s self-efficacy for quitting smoking and self-efficacy for maintaining PA (Boudreaux et al., 2003).

The evidence for PA as a strategy for supporting smoking cessation, however, is not strong. A Cochrane review of 11 randomized controlled trials examining PA as a smoking cessation strategy concluded that while exercise promotion did not appear to harm smoking cessation efforts, there was limited evidence that it helped (Ussher, 2005). Only one of the 11 trials found evidence for PA aiding smoking cessation at long-term follow up (Marcus et al., 1999). The program was highly structured, supervised, and promoted PA of vigorous intensity. A follow up study that promoted engagement in moderate PA and used more of a home-based approach failed to find an effect for long-term cessation relative to a standard cognitive behavioral cessation program (Marcus et al., 2005). In the Cochrane review, only two studies reported changes in PA, limiting our understanding of the feasibility of smokers making changes in their tobacco use and PA patterns concurrently (Ussher, 2005). A follow up study reported no long-term effect of a PA intervention on tobacco abstinence, but also reported no difference in PA levels between the intervention and control conditions (Ussher et al., 2007).

When quitting smoking, the timing of the PA program and the intensity of PA promoted (vigor vs. moderate) may be important. Moderate or “lifestyle” exercise programs may offer greater efficacy and practicality for dissemination (Dunn et al., 1998; King, 1998); greater participant adherence (King et al., 1995), and greater appeal to sedentary smokers (Ussher et al., 2001). The current study examined: (1) the impact of an extended relapse prevention program on increasing moderate to vigorous PA (MVPA) in adults enrolled in a tobacco cessation treatment trial; (2) whether changes in MVPA were associated with sustained abstinence from smoking; and (3) mechanisms by which MVPA may support sustained abstinence from smoking. Hypothesized mechanisms included enhanced psychological states, reduced withdrawal symptoms, improved health functioning, reduced weight gain, and greater motivation and self-efficacy to stay tobacco-free. Baseline correlates of PA also were examined with sample demographic and tobacco use characteristics.

Methods

Participants

Participants were 407 adults who smoked at least 10 cigarettes daily for 5 or more years and smoked within 30 min of awakening. The study, conducted in the San Francisco Bay Area, recruited smokers interested in quitting via direct mail and media advertisements. Recruitment spanned February 2003–December 2005 with the 24 week assessments completed in June 2006. The study was limited to English speakers. Exclusion criteria included contraindications to buproprion use (e.g., elevated seizure risk), nicotine patch (e.g., recent myocardial infarction, dermatitis), current pregnancy or lactation, and physical limitations to participation in moderate PA as assessed with the Physical Activity Readiness Questionnaire (PAR-Q) (Thomas et al., 1992). Additionally, smokers with current substance use problems, active psychiatric use, or current depression were excluded. The University of California, San Francisco Institutional Review Board approved the study, and participants provided informed consent.

Study design

All participants received a 12 week smoking cessation treatment consisting of nicotine patch therapy, sustained-release bupropion (150 mg twice a day), and five group sessions with the quit date set at week 3. Following the 12 week treatment, participants were randomized to no further treatment or one of four extended 40-week intervention conditions (see Fig. 1). Randomization was stratified by gender and smoking status at week 11. The extended conditions provided 40 more weeks of bupropion (52 weeks in total), or placebo, crossed with medication management, alone or with an extended relapse prevention program. The two extended relapse prevention conditions, with placebo or active bupropion, were combined for the current analyses to examine the impact of the PA intervention (shaded boxes in Fig. 1). The relapse prevention program focused on optimizing health while living smoke-free; consisted of 11 individual sessions staggered over 40 weeks time; and covered ongoing motivation, social support, mood management, nicotine dependence and withdrawal, and weight gain prevention through promotion of moderate to vigorous PA (Fiore et al., 2000). The current paper focuses on the impact of the two dedicated PA sessions of the relapse prevention intervention, delivered at weeks 16 and 20, and described below.

PA intervention

At week 14, participants receiving the relapse prevention program (n = 163) were provided a Yamax pedometer and instructed to track their steps for 2 weeks to provide a baseline indication of their PA level. Participants were to wear the pedometer every day all day, except when sleeping, swimming, or showering; record their steps at the end of each day; and reset the pedometer each morning. A form was provided to record time spent in activity not assessed by the pedometer (e.g., swimming, biking) for study counselors to convert into step estimates. An inexpensive and unobtrusive tool that captures varied levels and kinds of PA, pedometers have established validity and reliability (Felson et al., 2006; Tudor-Locke et al., 2001, 2002) and are increasingly being used to promote PA (Meron et al., 2007; Rooney et al., 2003; Stovitz et al., 2005).

At week 16, counselors entered participants’ recorded steps into an Excel-based program graphing the counts relative to the 10,000 steps/day goal (Tudor-Locke and Bassett, 2000). The program calculated participants’ mean steps/day (and recommended) an 10% increase in daily steps for the next 2 weeks. Counselors reviewed the printed report with participants and provided encouragement and support with increasing PA to meet their individual goals. At week 20, counselors entered participants’ step recording for the previous 4 weeks, reviewed progress in meeting the step goals, and printed a second report with updated goals reflecting a further 10% increase. Over the remaining 20 weeks of the extended relapse prevention program, ongoing step monitoring was encouraged with biweekly 10% increases in steps towards meeting the 10,000 steps/day goal. The PA program was designed to be individually tailored, encourage reasonable increases in PA over time, and brief and easy for master’s level counselors to implement.

Measures

The following measures were administered to all participants at baseline and weeks 12 and 24, unless otherwise indicated.

Tobacco measures

Tobacco Use was assessed as the number of cigarettes smoked in the past 7 days verified with an expired air carbon monoxide (CO) level using a Bedfont Smokerlyzer. At follow up assessments, nonsmoking status was defined as no use of tobacco in the past 7 days and a CO < 11 (SRNT Subcommittee on Biochemical Verification, 2002). Sustained abstinence was defined as being smoke-free at both weeks 12 and 24. Fagerström Test of Nicotine Dependence assessed level of dependence to nicotine at baseline (Heatherton et al., 1991). Thoughts about Abstinence scale assessed desire, expectancy of success, and anhedonia difficulty with quitting smoking rated on 10-point scales and abstinence goal (Hall et al., 1990); Minnesota Nicotine Withdrawal Scale (MNWS) assessed withdrawal symptoms over the past 24 h (Hughes and Hatsukami, 1986).

PA Measure

International Physical Activity Questionnaire (IPAQ). short form (7-items) assessed time spent sitting, walking, and engagement in other moderate and vigorous PA over the past 7-days. The measure specifies broad PA domains including transportation and household chores. The outcome variable for our analyses was total minutes of MVPA. The IPAQ, used widely in the literature, has demonstrated adequate reliability and criterion validity against accelerometers (Craig et al., 2003; Fogelholm et al., 2006; Hagstromer et al., 2006), yet has shown problems with skew and is often analyzed using a log transformation (De Bourdeaudhuij et al., 2003; Rzewnicki et al., 2003). In the current sample, a log10 transformation of participants’ MVPA minutes at week 12 approximated a normal distribution and correlated significantly (r = 0.33, p = 0.048) with intervention participants’ objective pedometer counts during the initial 2-week baseline period (weeks 14 to 16).

Mood and health measures

Profile of Mood States (POMS) provides six subscales (Depression, Tension, Anger, Confusion, Fatigue, and Vigor) and a Total Mood Disturbance score. POMS scores are predictive of smoking relapse (McNair et al., 1971) and used widely in the sport and exercise psychology field (LeTien, 2000). Perceived Stress Scale, 10-items, assessed frequency of experienced stressors in the past month (Cohen et al., 1983). Medical Outcome Studies 36-item Short-Form Health Survey (SF-36) provides a global self-rating of health and composite scales of general physical and mental health functioning (Ware et al., 1997). Body Mass Index (BMI) was assessed in stock feet with a balance beam scale and calculated as height in inches divided by weight in kilograms squared.

Demographic measure

Participants reported their gender, age, ethnicity or race, education, employment, marital status, and income.

Analyses

Analyses were performed using SAS 9.1.3. Pearson correlations examined associations among baseline PA levels and participant demographic and smoking characteristics. Analyses compared outcomes for participants in the two extended relapse prevention conditions (referred to as the PA intervention) to the three other conditions (referred to as the control condition). For aim 1, we ran a repeated mixed model analysis to compare changes in MVPA from baseline to weeks 12 and 24 based on randomization to the PA intervention. The comparison groups’ sample sizes provided 80% power to
detect a difference in MVPA levels of moderate magnitude (Cohen's $d = 0.28$) at an alpha level of .05. For aim 2, we ran a logistic regression to examine changes in MVPA as a function of continued abstinence, controlling for the 5-group treatment condition assignment, thereby controlling for effects of the medication assignment (bupropion or placebo). Lastly, for aim 3, we ran Pearson correlations to test associations between increased MVPA and hypothesized constructs, among participants with sustained abstinence at week 24. In all analyses, IPAQ data were analyzed as log10 MVPA minutes.

**Results**

**Participant baseline characteristics**

The sample was 61% male with a mean age of 40.7 years (SD=9.8). Race or ethnic identification was Caucasian (71%), African American (8%), Asian/Pacific Islander (6%), Hispanic (3%), multiracial (10%), and other (2%). Most participants (74%) had attended some college; 45% held at least a bachelor’s degree; 72% were employed. The measured BMI of the sample averaged 26 (SD=5) for men and 26 (SD=6) for women at baseline; 54% of the men and 47% of the women were classified as overweight or obese. Participants smoked $M = 18.6$ cigarettes per day (SD=7.9), had an FTND score of $M = 4.9$ (SD=2.1), and a CO reading of $M = 21.6$ ppm (SD=11.3) at baseline.

The two groups did not differ on any demographic or tobacco-use characteristic; however, log10 MVPA minutes were significantly lower at both baseline, $F(1,354)=4.98$, $p=0.026$, and week 12, $F(1,266)=5.61$, $p=0.019$, for participants in the PA intervention relative to the control condition (see Fig. 2). Based on pedometer step recording during weeks 14 to 16, 76% of participants in the PA intervention averaged less than the recommended 10,000 steps/day goal.

**Baseline correlates of PA**

Participants’ MVPA at baseline did not differ significantly by gender, age, education, or employment status or for any of the tobacco use variables (cigarettes per day, FTND, Thoughts about Abstinence, or CO level). Baseline MVPA correlated significantly with the POMS subscales of Tension ($r = -0.12$), Confusion ($r = -0.13$), Depression ($r = -0.16$), Fatigue ($r = -0.16$), and Vigor ($r = 0.23$), and the Total Mood Disturbance score ($r = -0.17$), all $p$-values <.05; the Perceived Stress...
Intervention participants who sustained abstinence at week 24 and control participants by sustained abstinence status at week 24. Relapsed (week 24, odds ratio = 1.84, sustained smoking abstinence at week 24. Controlling for treatment whether changes in log10 minutes MVPA were associated with outcomes paper for the study. For the current analyses, we examined Change in PA and sustained abstinence.

Abstinence rates by condition will be reported in the main outcomes paper for the study. For the current analyses, we examined whether changes in log10 minutes MVPA were associated with sustained smoking abstinence at week 24. Controlling for treatment condition, increased MVPA predicted sustained smoking abstinence at week 24, odds ratio = 1.84, p = .028 (95% CI: 1.07, 3.05).

Changes in log10 minutes MVPA were examined for intervention and control participants by sustained abstinence status at week 24. Intervention participants who sustained abstinence at week 24 increased their MVPA (M = 17, SD = .48), control participants who were abstinent (M = .01, SD = .50) and intervention participants who relapsed (M = .00, SD = .52) had no change, and the MVPA of control participants who returned to smoking at week 24 declined (M = –.15, SD = .55).

Among subjects with sustained abstinence (n = 153), increased MVPA was associated with increased vigor (r = .23, p = .025) and decreased perceived difficulty with staying smoke-free (r = –.21, p = .038) from baseline to week 24. Change in MVPA was not significantly correlated with change in other psychological states as measured by the POMS nor change in withdrawal symptoms, perceived stress, weight gain, or health functioning.

Discussion

The current study examined promotion of PA as part of an extended relapse prevention program for smoking cessation. The PA component was brief (2 sessions), individualized, encouraged self-monitoring with a pedometer, and promoted gradual increases in lifestyle MVPA. As hypothesized, we found significant increases in MVPA from baseline to week 24 among participants receiving the PA intervention, whereas MVPA among control participants declined. Among intervention participants who did their pedometer recording, daily steps increased an average of 16% or 1061 steps between the two PA sessions. In a recent review of pedometer use, increases averaged 2491 steps/day in randomized controlled intervention trials and 2183 in observational studies, reflecting a 27% increase over baseline levels (Bravata et al., 2007). The pedometer interventions reviewed tended to be of longer duration than that employed in the current study, M = 18 weeks (range 3 to 104 weeks).

Change in MVPA significantly predicted sustained abstinence from smoking at week 24. Increases in PA were associated with a greater likelihood of sustained abstinence from smoking, while relapse to smoking was associated with decline in activity. The findings are consistent with a recent prospective 7-year observational study with 750 Japanese men in which increased habitual exercise was associated with smoking cessation, while smoking relapse was associated with reduced habitual exercise (Nagaya et al., 2007).

Examining MVPA changes by abstinence status and condition, MVPA increased among PA intervention participants who sustained abstinence, remained unchanged among intervention participants who relapsed or control participants with sustained abstinence, and declined among control participants who relapsed. The PA intervention appeared to increase PA among participants who quit smoking and mitigate declines in PA among those who relapsed.

Among participants with sustained abstinence at week 24, increased MVPA was associated with decreased perceived difficulty with remaining smoke-free and an increased state of vigor. Engagement in PA may have reinforced participants’ commitment to a healthy lifestyle, which did not include smoking. In the literature, a significant cross-sectional association has been found between self-efficacy for smoking cessation and exercise adoption (King et al., 1996). Individuals working on increasing their PA seem confident about decreasing their smoking and vice versa. Previous studies also have reported higher ratings of vigor among adults who are more physically active (Leunes, 2000). Engagement in PA may help to offset the fatigue and sleep problems characteristic of nicotine withdrawal (American Psychiatric Association [APA], 1994).

The lack of significant correlations between changes in MVPA and other nicotine withdrawal symptoms and BMI may reflect the timing of the intervention and assessment schedule. The PA sessions came 13 weeks after the scheduled quit date, likely too late to impact most nicotine withdrawal symptoms, which typically last only 2 to 4 weeks (APA, 1994). For weight gain prevention, the week 24 assessment (only 4 weeks after the second PA session) may have been too soon to detect an effect.

Strengths of the current study include a large sample size and use of a validated PA self-report measure. Though used largely as a surveillance tool in the literature, the IPAQ demonstrated sensitivity to

Scale (r = –.12, p = .03); and the SF-36 global rating of health (r = .20, p = .001) and the general physical functioning composite score (r = .11, p = .04). MVPA correlated significantly with BMI for women (r = –.22, p < .01), but not men, r = 0.03.

Change in PA overtime by condition

In a repeated mixed model analysis, participants randomized to the PA intervention significantly increased their MVPA over time relative to control participants, F (1,475) = 3.95, p = .047. Fig. 2 shows the change in log10 minutes of MVPA over time by condition. Assessments at baseline and week 12 allowed for an extended baseline assessment of PA since the PA sessions occurred at weeks 16 and 20. The significant change in MVPA over time by condition reflected both an increase in MVPA among participants in the PA intervention group coupled with a decline in MVPA among control participants.

Pedometer data were available at weeks 16 and 20 for 24 of the 163 participants in the relapse prevention condition. Pedometer data for these participants indicated a significant increase in average daily steps from the first to the second PA session, paired samples t (23) = 2.36, p = .027. The change in steps averaged an increase of 16% (see Fig. 3). Comparison of the 24 PA intervention participants with consistent step recording to the other PA intervention participants indicated no significant difference on any of the measured demographic, tobacco use, health, or PA measures.

Change in PA and sustained abstinence

Abstinence rates by condition will be reported in the main outcomes paper for the study. For the current analyses, we examined whether changes in log10 minutes MVPA were associated with sustained smoking abstinence at week 24. Controlling for treatment condition, increased MVPA predicted sustained smoking abstinence at week 24, odds ratio = 1.84, p = .028 (95% CI: 1.07, 3.05).

Changes in log10 minutes MVPA were examined for intervention and control participants by sustained abstinence status at week 24. Intervention participants who sustained abstinence at week 24 increased their MVPA (M = 17, SD = .48), control participants who were abstinent (M = .01, SD = .50) and intervention participants who relapsed (M = .00, SD = .52) had no change, and the MVPA of control participants who returned to smoking at week 24 declined (M = –.15, SD = .55).

Correlates of change in MVPA among participants with sustained abstinence

Among subjects with sustained abstinence (n = 153), increased MVPA was associated with increased vigor (r = .23, p = .025) and decreased perceived difficulty with staying smoke-free (r = –.21, p = .038) from baseline to week 24. Change in MVPA was not significantly correlated with change in other psychological states as measured by the POMS nor change in withdrawal symptoms, perceived stress, weight gain, or health functioning.

Discussion

The current study examined promotion of PA as part of an extended relapse prevention program for smoking cessation. The PA component was brief (2 sessions), individualized, encouraged self-monitoring with a pedometer, and promoted gradual increases in lifestyle MVPA. As hypothesized, we found significant increases in MVPA from baseline to week 24 among participants receiving the PA intervention, whereas MVPA among control participants declined. Among intervention participants who did their pedometer recording, daily steps increased an average of 16% or 1061 steps between the two PA sessions. In a recent review of pedometer use, increases averaged 2491 steps/day in randomized controlled intervention trials and 2183 in observational studies, reflecting a 27% increase over baseline levels (Bravata et al., 2007). The pedometer interventions reviewed tended to be of longer duration than that employed in the current study, M = 18 weeks (range 3 to 104 weeks).

Change in MVPA significantly predicted sustained abstinence from smoking at week 24. Increases in PA were associated with a greater likelihood of sustained abstinence from smoking, while relapse to smoking was associated with decline in activity. The findings are consistent with a recent prospective 7-year observational study with 750 Japanese men in which increased habitual exercise was associated with smoking cessation, while smoking relapse was associated with reduced habitual exercise (Nagaya et al., 2007).

Examining MVPA changes by abstinence status and condition, MVPA increased among PA intervention participants who sustained abstinence, remained unchanged among intervention participants who relapsed or control participants with sustained abstinence, and declined among control participants who relapsed. The PA intervention appeared to increase PA among participants who quit smoking and mitigate declines in PA among those who relapsed.

Among participants with sustained abstinence at week 24, increased MVPA was associated with decreased perceived difficulty with remaining smoke-free and an increased state of vigor. Engagement in PA may have reinforced participants’ commitment to a healthy lifestyle, which did not include smoking. In the literature, a significant cross-sectional association has been found between self-efficacy for smoking cessation and exercise adoption (King et al., 1996). Individuals working on increasing their PA seem confident about decreasing their smoking and vice versa. Previous studies also have reported higher ratings of vigor among adults who are more physically active (Leunes, 2000). Engagement in PA may help to offset the fatigue and sleep problems characteristic of nicotine withdrawal (American Psychiatric Association [APA], 1994).

The lack of significant correlations between changes in MVPA and other nicotine withdrawal symptoms and BMI may reflect the timing of the intervention and assessment schedule. The PA sessions came 13 weeks after the scheduled quit date, likely too late to impact most nicotine withdrawal symptoms, which typically last only 2 to 4 weeks (APA, 1994). For weight gain prevention, the week 24 assessment (only 4 weeks after the second PA session) may have been too soon to detect an effect.

Strengths of the current study include a large sample size and use of a validated PA self-report measure. Though used largely as a surveillance tool in the literature, the IPAQ demonstrated sensitivity to

Fig. 3. Average daily step counts among PA intervention participants with pedometer recording at both weeks 12 to 14 and weeks 16 to 20 (n = 24). The study was conducted in San Francisco, CA with recruitment started in February 2003 and the week 24 assessments completed in June 2006.
detecting changes overtime associated with an intervention. A limitation of the IPAQ, however, was the high degree of skew making use of the raw data for examining baseline PA levels misleading. Despite this limitation, brief measures, such as the IPAQ, are particularly useful in studies targeting and assessing multiple health behaviors given concerns with respondent burden. In the current sample, self-reported MVPA correlated significantly with objective pedometry counts.

The study is limited in that it focused on short-term effects of a PA intervention on smoking abstinence. Despite a randomized design, participants in the relapse prevention group reported lower levels of MVPA at baseline relative to control participants. The difference was stable with the repeated baseline assessment design, apparent at both the baseline and week 12 assessments. The low compliance with pedometry monitoring also limits the study findings. Only 15% of participants in the PA intervention provided 6 weeks of pedometry monitoring. The PA intervention was part of an extended relapse prevention intervention with multiple objectives: nicotine withdrawal, mood management, social support, ongoing motivation, and weight gain prevention through PA promotion. Given the multiple foci, participants may have opted to focus on the issues of greatest concern or interest to them. A study of smokers with severe mental illness reported that 63% were interested in assistance to increase their PA levels while quitting smoking (Faulkner et al., 2007). Given the high rates of tobacco use and inactivity among persons with mental illness, this group presents a unique population worthy of study with perhaps even greater potential synergism for PA’s effects on enhancing mood and reducing nicotine withdrawal symptoms.

The leading causes of morbidity and mortality in the US – heart disease, stroke, diabetes, and cancer – are influenced by tobacco use and sedentary lifestyles. Risk behaviors have been shown to cluster among and tobacco users, and in particular, tend to have poor behavioral profiles, with about 92% of smokers having at least one additional risk behavior (Fine et al., 2004; Klesges et al., 1990; Pront et al., 2004). In the 2001 National Health Interview Study, 70% of current smokers were classified as physically inactive (Fine et al., 2004). Interventions that address multiple behaviors, such as tobacco use and PA, have the potential to offer greater health benefits, more adequately address participants’ behavioral profiles, maximize health promotion opportunities, and reduce health care costs.

The current study demonstrated that the addition of a low cost, two session PA program to a smoking cessation intervention served to increase participants’ MVPA with changes predictive of sustained abstinence at 24 weeks. The timing of the PA sessions (13 weeks post quit date), promotion of lifestyle activity of moderate intensity, and the tailoring of step goals to participants’ baseline activity levels are factors that likely contributed to the significant changes observed.

Acknowledgments

This work was supported by the National Institute on Drug Abuse (#R01 DA015732, #K05 DA016752, #K23 DA018691 and #P50 DA09253) and the State of California Tobacco-Related Disease Research Program (#13KT-0152). The authors have no financial interests related to the material in the manuscript. The study was presented orally at the Annual Meeting of the Society of Behavioral Medicine in San Diego, CA on March 28, 2008. We thank Kevin Ahern for his assistance with data management.

References


Ware, J.E., Snow, K.K., Kosinski, M., Gandek, B., 1997. SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, New England Medical Center, Boston, MA.